Stockreport

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 1 [Read more]